30 RESPIRATORY

We are advancing ground-breaking research using 30Technology™ to treat respiratory infection and disease.

RESEARCH PRIORITIES

CYSTIC FIBROSIS

In the US, there are approximately 1000 new diagnoses of cystic fibrosis each year. 85% of the mortality associated with those with cystic fibrosis is a result of lung disease, which begins because of the inflammation and debilitated mucociliary clearance which leads to chronic airway infection.

TUBERCULOSIS
Worldwide, TB is one of the top 10 causes of death and the leading cause of death from a single infectious agent. It was estimated to be responsible for roughly 1.3 million deaths in 2017, with 10 million people developing TB according to the WHO.

ASPERGILLOSIS
The incidence of aspergillosis in immunocompromised patients undergoing organ or stem cell transplantation can be as high as 10% to 20% with up to 50% mortality reported.

30 TECHNOLOGY is developing and defining new models of care to treat many serious medical conditions by enhancing the body’s healing and defence mechanisms.

30 TECHNOLOGY Therapeutic Nitric Oxide